Patients who develop chronic fibrotic liver disease, caused by viral or metabolic aetiologies,
are at a high risk of developing hepatocellular carcinoma (HCC). Even after complete HCC …

Hepatocellular carcinoma (HCC) is one of the most prevalent cancers globally. In contrast to
the declining death rates observed for all other common cancers such as breast, lung, and …

This guidance provides a data-supported approach to the diagnosis, staging, and treatment
of patients diagnosed with hepatocellular carcinoma (HCC). A guidance document is …

Simple Summary Anti-PD-1/PD-L1 and anti-CTLA-4-based immune checkpoint blockade
(ICB) immunotherapy have recently emerged as a breakthrough in human cancer treatment …

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths and
the fifth most common cancer worldwide. Most of these patients are seen with advanced …

The most common primary liver cancer is hepatocellular carcinoma (HCC), and its mortality
rate is increasing globally. The overall 5-year survival of patients with liver cancer is …

Simple Summary Non-homeostatic cytokine expression during hepatocellular
carcinogenesis, together with simple and inexpensive cytokine detection techniques, has …

Hepatocellular carcinoma (HCC) represents a worldwide health matter with a major care
burden, high prevalence, and poor prognosis. Its pathogenesis mainly varies depending on …

Circulating full-length osteopontin (FL-OPN) is elevated in plasma from patients with various
infectious diseases, such as adult T-cell leukemia, Mycobacterium tuberculosis (TB) …

Hepatocellular carcinoma (HCC) is a highly prevalent and lethal cancer globally. Over 90%
of HCC cases arise in the context of liver cirrhosis, and the severity of the underlying liver …